/
DRUG
$69.18+$3.39 (+5.15%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$645.5M
10M shares
52-week range
$23.98 – $123.75
45% from low
Exchange
NASDAQ
CS
Borrow rate
1.77%
Moderate
Price (6 mo)
Loading chart…
Change+$27.88
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $126.0K | $354.9K | $6.3M | $12.2M | $5.0M | $1.2M | $11.1M |
| Operating income | −$236.2K | −$474.9K | −$8.6M | −$15.0M | −$7.4M | −$2.8M | −$13.9M |
| EBITDA | $0 | $0 | −$27.6K | −$15.0M | −$7.3M | −$2.7M | −$12.2M |
| Net income | −$236.2K | −$480.4K | −$8.7M | −$15.0M | −$7.4M | −$2.8M | −$12.2M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.06 | -0.38 | -4.74 | -6.15 | -1.98 | -0.65 | -1.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-6.60 | $-7.97–$-5.32 | 5 |
| 2027 | $34M | $-12.42 | $-12.79–$-12.04 | 5 |
| 2028 | $0 | $-14.62 | $-18.22–$-8.05 | 6 |
| 2029 | $0 | $-16.25 | $-16.25–$-16.25 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$8.36
Price
$69.18
Implied downside
-88%
Peer comparison
Bright Minds Biosciences Inc. Common Stock
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
www.brightmindsbio.com- Employees
- 25
- IPO / List date
- Mar 8, 2021
Held by traders on TradeandTell
No one on the platform currently holds DRUG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 3,500 | $212.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-07-14 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded DRUG yet.
